Human Tumour Xenografts in Anticancer Drug Development: ESO Monographs
Editat de Benjamin Winograd, Michael Peckham, Herbert M. Pinedoen Limba Engleză Paperback – 6 ian 2012
Din seria ESO Monographs
- 5% Preț: 697.15 lei
- 5% Preț: 697.15 lei
- 5% Preț: 694.81 lei
- 5% Preț: 704.13 lei
- 5% Preț: 695.89 lei
- 5% Preț: 692.69 lei
- 5% Preț: 692.69 lei
- 5% Preț: 697.49 lei
- 5% Preț: 698.20 lei
- 5% Preț: 699.63 lei
- 5% Preț: 695.16 lei
- 5% Preț: 691.93 lei
- 5% Preț: 693.38 lei
- 5% Preț: 694.09 lei
- 5% Preț: 693.38 lei
- 5% Preț: 695.89 lei
- 5% Preț: 699.63 lei
- 5% Preț: 693.38 lei
- 5% Preț: 1066.34 lei
- 5% Preț: 1067.77 lei
- 5% Preț: 699.28 lei
- 5% Preț: 696.42 lei
- 5% Preț: 1065.28 lei
- 5% Preț: 693.38 lei
- 5% Preț: 695.72 lei
- 5% Preț: 355.96 lei
- 5% Preț: 695.52 lei
- 5% Preț: 700.90 lei
- 5% Preț: 695.52 lei
- 5% Preț: 698.05 lei
- 5% Preț: 696.08 lei
- 5% Preț: 703.77 lei
- 5% Preț: 352.40 lei
- Preț: 381.68 lei
Preț: 1071.91 lei
Preț vechi: 1128.33 lei
-5% Nou
Puncte Express: 1608
Preț estimativ în valută:
205.21€ • 213.30$ • 170.14£
205.21€ • 213.30$ • 170.14£
Carte tipărită la comandă
Livrare economică 05-19 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783642732546
ISBN-10: 3642732542
Pagini: 164
Ilustrații: XV, 143 p. 4 illus.
Dimensiuni: 210 x 280 x 9 mm
Greutate: 0.41 kg
Ediția:Softcover reprint of the original 1st ed. 1988
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria ESO Monographs
Locul publicării:Berlin, Heidelberg, Germany
ISBN-10: 3642732542
Pagini: 164
Ilustrații: XV, 143 p. 4 illus.
Dimensiuni: 210 x 280 x 9 mm
Greutate: 0.41 kg
Ediția:Softcover reprint of the original 1st ed. 1988
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria ESO Monographs
Locul publicării:Berlin, Heidelberg, Germany
Public țintă
ResearchCuprins
I. Biological Behaviour of Human Tumours Transplanted in Mice and the Evaluation of Therapeutic Response.- The Therapeutic Response of a Variety of Human Tumour Xenografts.- Biology of Human Ovarian Cancer Xenografts.- Representativity of Xenografts for Clinical Cancer. Tumor and Host Characteristics as Variables of Tumor Take Rate.- II. Prediction of Tumour Response for the Individual Patient by the Human Tumour Xenograft.- Comparison of Tumor Response in Nude Mice and in Patients.- III. Prediction of Antitumour Activity per Tumour Type by the Human Tumour Xenograft.- Conventional Agents in Human Ovarian Cancer Xenografts.- Activity of Conventional Drugs in Head and Neck Cancer Xenografts.- Preclinical Drug Evaluation with Human Melanoma Xenografts.- Lung Xenografts as a Predictive Screen for Antineoplastic Agents.- Chemotherapy Studies in Human Non-Small Cell Lung Cancer Xenografts Transplanted in Immune-Deprived Mice.- Establishment and Response to Chemotherapy of Human Cervical Carcinoma Xenografts.- The Usefulness of the Nude Mouse Model for Predicting the Chemosensitivity of Human Tumors. Studies in Malignant Melanoma.- IV. Preclinical Evaluation of Analogs of Known Anticancer Agents.- Screening of Analogs in Human Ovarian Cancer Xenografts.- Predictability of Clinical Response of Several Human and Murine Tumor Models to Four Anthracycline Derivatives.- V. New Drugs.- Activity of Six New Drugs in Head and Neck Cancer Xenografts.- Activity of Metallocene Complexes Against Human Tumours Heterotransplanted into Athymic Mice.- VI. Human Tumour Xenografts in the Development of Biological Response Modifiers.- The Effect of Human and Murine Interferons on Human Tumour Xenografts.- Biodistribution and Therapeutic Efficacy of a Monoclonal Antibody-Methotrexate Conjugate inMice.- The Effect of Interferon-Alpha on the Activity of Cytotoxic Drugs in Bronchial Carcinoma Xenografts.- The Nude Mouse for the Study of Immunotoxins.- VII. Human Tumour Xenografts in Drug Screening.- Proposal for the Application of Xenografts in Screening for New Anticancer Agents and in Selecting Tumor Types for Phase II Clinical Trials.- Human Tumour Xenograft Models for Use with an In Vitro-Based, Disease-Oriented Antitumour Drug Screening Program.- VIII. Importance of Drug Resistance in Screening.- Mechanisms of Drug Resistance in Screening.- Circumvention of Inherent Resistance with Verapamil in a Human Tumour Xenograft.- IX. Proferred Papers at the E. S. O. Seminar.- Clonogenic Assay Screening Study Group (CASSG): Contribution to an EORTC Drug Screening Programme.- Polyamine Uptake by Malignant Brain Tumour Xenografts in Nude Mice.- The Activity for a Novel Niteosourea (TCNU) in Human Lung Cancer Xenografts.- Xenografts in Pharmacologically Immunosuppressed Mice as a Model to Test the Chemotherapeutic Sensitivity of Human Tumours.- New Tissue-Specific Metastasis Models in Adult Nude Mice.- Fractionated Irradiation of Human Tumor Xenografts in Athymic Nude Mice.- An Animal Model for Human Tumor Xenografts.- Xenografted Human Tumors in Preclinical Drug Design.- Growth in Nude Mice of a T-Cell Line from a Case of Acute Lymphoblastic Leukaemia: A Model for Experimental Immunotherapy of Human Neoplasia.- 5-Fluorouracil (5-FU) + Cis-diamminedichloroplatinum (DDP) Treatment of Human Colorectal Tumor Xenografts.- Inter and Intra-Tumor Variation in the Response to Chemotherapy of Human Small Cell Carcinoma of the Lung (SCCL) Grown in Nude Mice.- Human Carcinoma Cell Lines Xenografted in Athymic Mice: Biological and Antigenic Characterization of an Intra-Abdominal Model.- Squamous Cell Carcinoma Xenografts as a Model for the Study of Drug-Induced Cell Kinetic Changes in Head and Neck Cancer.